摘要

关节内使用一种由葡萄糖胺和硫酸软骨素与透明质酸组成的独特组合的医疗器械

作者(年代):Nuretin Heybeli

膝骨关节炎(KOA)是一个主要的健康问题。长期以来，注射与使用玻尿酸的一般定义下粘补充。然而，随着最近生物技术的进步，我们可以走得更远。葡萄糖胺和硫酸软骨素是很有前途的治疗方法，两者都显示出口服配方的有效性。葡萄糖胺是糖胺聚糖结构的基本前体，随后是软骨中聚集蛋白和其他蛋白聚糖结构的基本前体。硫酸软骨素(CS)是一种天然的糖胺聚糖发现在软骨的聚集蛋白分子的结构。它对软骨有许多有益的生物学特性，包括抗炎活性、伤口愈合、抑制负责软骨降解的酶的能力，以及在细胞水平上帮助恢复关节炎关节功能的生物活性。在其他特性中，由于其结构保证了负电荷，CS负责软骨的水潴留。它被认为是治疗关节缺损的一种可能的候选者。硫酸软骨素钠的安全性得到了多项精心设计的人体临床试验和动物研究的支持。 ???Genvisc??? is the medical device that combines these three essential molecules. In this study, We aimed to assess the feasibility and safety of repeated intra-articular knee injection of this unique combination to treat KOA as well as efficacy. The study protocol was approved in April 2016 by the Ethics Committee of Trakya University. After the approval of the local ethics committee, patients suffering from KOA with Kellgren-Lawrence grade II and III, aged between 35 to 80 years were included. Patients were prospectively evaluated at baseline and then at 2, 6 and 12 months of follow-up using the International Knee Documentation Committee (IKDC) subjective score (main outcome), Knee injury and Osteoarthritis Outcome Score, EuroQol visual analog scale and Tegner score. The range of motion, transpatellar circumference, patient satisfaction and adverse events were also recorded. A significant improvement was found in the study group with acceptable side effects.